Big-name drugmakers play heart-drug roulette

Goodbye to Lipitor and Plavix; hello to new cardiovascular blockbusters? That's the gamble Big Pharma is taking, as drugmakers from Merck ($MRK) to Sanofi ($SNY) to GlaxoSmithKline ($GSK) sink beaucoups bucks into three types of potential heart treatments. Report